Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A papaverine-atropinic drug with anticholinergic and smooth muscle spasmolytic effects. In some countries it is used to treat nephritic, hepatobiliary and intestinal colic, dysmenorrhea and in labor augmentation (Palshetkar 2020). It is erroneously indicated in headaches, odontalgias, arthralgias and nephritic colic that have nothing to do with smooth muscle spasms (Torres 2014, Zangronis 2006). There is also no good evidence that antispasmodics are useful during labor (Rohwer 2012). Oral, intramuscular and intravenous administration.
At the date of the last update we found no published data on its excretion in breast milk.
The scarcity of known pharmacokinetic data does not allow predicting its possible excretion in breast milk.
Product with very few bibliographic references and/or very old, marketed in very few countries.
It may cause drowsiness, obnubilation, nausea, vomiting, dry mouth, dysuria, constipation, tachycardia or nervousness. (CECMED 2017)
An overdose of oral camilophine in 2 infants less than 1 month old produced symptoms similar to those of opioid intoxication that was reversed with naloxone. (Schvartsman 1988)
Pending further published data on this drug in relation to lactation, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.
Translated with www.DeepL.com/Translator (free version)